Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TGRX-326 in Advanced ALK+ or ROS1+ NSCLC
NCT05441956Phase 1Active, not recruiting
- Sponsor
- Shenzhen TargetRx
- Start
- Apr 2021
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of deulorlatinib in non-small cell lung cancer (NSCLC), sponsored by Shenzhen TargetRx. Primary endpoints: Maximal Tolerated Dose, Recommended Phase II Dose at 1 year and 2 more. Started Apr 2021; status: active, not recruiting.
02
Drugs
deulorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05441956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05441956.